# Supriya Lifescience Limited (SUPRIYA)

> SUPRIYA closed at ₹860.00 on 30 Oct 2026, trailing P/E 34.9, market cap ₹6,922 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Supriya Lifescience Limited (NSE: SUPRIYA) closed at ₹860.00 on 30 Oct 2026, +16.4% over one year, against a 52-week range of ₹545.50 – ₹1,085.00.

In the quarter ended 30 Jun 2026 (standalone, filed 13 Aug 2026) it reported revenue of ₹190 cr and net profit of ₹24 cr, a 12.7% net margin; revenue grew 30.8% and profit fell 14.0% year on year.

On four consecutive filed quarters its trailing P/E is 34.9; since 27 May 2025 its own P/E has ranged from 24.0 to 40.6 (median 31.3), and today's reading is higher than 84% of those 353 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 8.0%, ROCE 13.3%, debt-to-equity 0.00, Piotroski F-score 5 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 49% of 63 sector peers; PBT margin higher than 64% of 63 sector peers; ROE higher than 16% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹860.00 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -10.6% / +33.8% / +16.4% |
| 52-week low – high | ₹545.50 – ₹1,085.00 |
| Market capitalisation | ₹6,922 cr |
| Trailing P/E | 34.9 |
| Price / book | 5.78 |
| EV / EBITDA | 22.9 |
| Earnings yield | 2.9% |
| TTM EPS | ₹24.65 |
| TTM net profit | ₹198 cr |
| Quarter revenue | ₹190 cr |
| Quarter net profit | ₹24 cr |
| Net margin | 12.7% |
| Revenue growth (YoY) | +30.8% |
| Profit growth (YoY) | -14.0% |
| Return on equity | 8.0% |
| ROCE | 13.3% |
| Debt / equity | 0.00 |
| Current ratio | 4.40 |
| Free cash flow | ₹34 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹17.2 cr |

## Questions

### What is the P/E ratio of Supriya Lifescience Limited?

Supriya Lifescience Limited's trailing P/E is 34.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 27 May 2025 its P/E has ranged 24.0–40.6.

### What were Supriya Lifescience Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Supriya Lifescience Limited reported revenue of ₹190 cr and net profit of ₹24 cr (standalone), filed with the exchange on 13 Aug 2026.

### What is Supriya Lifescience Limited's ROE?

Return on equity is 8.0% based on the balance sheet dated 31 Mar 2026.

### Does Supriya Lifescience Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.

### What is SUPRIYA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, SUPRIYA traded between ₹545.50 and ₹1,085.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/SUPRIYA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._